Ambry Genetics +RNAinsight
Oct 01, 2019
Ambry Genetics has launched +RNAinsight, a combined DNA and RNA genetic test for hereditary cancer syndromes that is designed to return more certain results to patients by using RNA sequencing to definitively classify otherwise ambiguous genetic alterations. While the RNA aspect of the test does not include all known cancer risk genes, it does focus on a subset that includes BRCA1 and 2, TP53, PTEN, and PALB2, among others. Ambry said that the turnaround time for the combined test matches the company's DNA-only hereditary cancer panel.